Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Frequently asked questions
What sector does Matinas BioPharma Holdings Inc (MTNB) operate in?
Matinas BioPharma Holdings Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Matinas BioPharma Holdings Inc (MTNB) current stock price?
As of the latest data, Matinas BioPharma Holdings Inc stock price is $1.66, with a previous close of $1.70. Matinas BioPharma Holdings Inc lost -$0.04 in the last trading session, representing a -2.39% loss.
What is Matinas BioPharma Holdings Inc (MTNB) current market capitalization?
Matinas BioPharma Holdings Inc market cap is approximately 1.63 million.
What is Matinas BioPharma Holdings Inc (MTNB) Earnings Per Share (EPS)?
The trailing EPS is -$17.25.
What is Matinas BioPharma Holdings Inc (MTNB) EBITDA?
Matinas BioPharma Holdings Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.78 million.
Does Matinas BioPharma Holdings Inc (MTNB) pay dividends?
No. Matinas BioPharma Holdings Inc does not pay a dividend.
When is Matinas BioPharma Holdings Inc (MTNB) next earnings report?
Matinas BioPharma Holdings Inc is expected to release its next earnings report on September 30, 2026.
What is Matinas BioPharma Holdings Inc (MTNB) beta (volatility) score?
Matinas BioPharma Holdings Inc has a beta of 1.703, suggesting it is more volatile than the market.
